α1-Antitrypsin deficiency. by Greene, Catherine M et al.
1 
 
α1-antitrypsin deficiency 
Catherine M. Greene1*, Stefan J. Marciniak2, Jeffrey Teckman3, Ilaria Ferrarotti4, Mark L. 
Brantly5, David A. Lomas6, James K. Stoller7 and Noel G. McElvaney1.  
 
 
 
1Department of Medicine, Royal College of Surgeons in Ireland Education and Research 
Centre, Beaumont Hospital, Dublin 9, Ireland.  
2Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. 
3Department of Pediatrics, Saint Louis University, Missouri, USA.  
4Department of Internal Medicine and Therapeutics Pneumology Unit, University of 
Pavia, Italy.  
5 Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida College 
of Medicine, Gainesville, Florida, USA.  
6UCL Respiratory , Division of Medicine, University College London, London, UK.  
7Education Institute and Respiratory Institute, Cleveland Clinic, Ohio, USA.  
 
 
Correspondence to: 
C.M.G.  
cmgreene@rcsi.ie  
 
  
2 
 
ABSTRACT  
α1-antitrypsin deficiency (A1ATD) is an inherited disorder caused by mutations 
in SERPINA1, leading to liver and lung disease. It is not a rare disorder but frequently 
goes underdiagnosed or misdiagnosed as asthma, chronic obstructive pulmonary disease 
(COPD) or cryptogenic liver disease. The most frequent disease-associated mutations 
include the S and Z alleles of SERPINA1, which lead to the accumulation of misfolded 
α1-antitrypsin in hepatocytes, ER stress, low circulating levels of α1-antitrypsin and liver 
disease. Currently, no cure for severe liver disease exists and the only management 
option is liver transplantation, when liver failure is life threatening. A1ATD-associated 
lung disease predominately occurs in adults and is caused principally by inadequate 
protease inhibition. Treatment of A1ATD-associated lung disease includes standard 
therapies that are also used for the treatment of COPD, in addition to the use of 
augmentation therapy (infusions of human plasma-derived, purified α1-antitrypsin). New 
therapies targeting the misfolded α1-antitrypsin or attempting to correct the underlying 
genetic mutation are currently under development.  
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α1-antitrypsin is a serine proteinase inhibitor, produced principally by hepatocytes 
but also by neutrophils, monocytes and epithelial cells of the lung and gut. It is a major 
circulating antiprotease in humans and its key function is the regulation of the proteolytic 
effects of neutrophil elastase in the lung, which can lead to a range of consequences 
including inflammation and changes in the extracellular matrix (ECM). In addition, α1-
antitrypsin is also an acute phase protein with anti-inflammatory and immuno-modulatory 
properties.  
α1-antitrypsin deficiency (A1ATD, Online Mendelian Inheritance in Man 
(OMIM) entry 107400) is a disorder caused by mutations in the SERPINA1 gene and is 
inherited in an autosomal and codominant pattern, indicating that the two copies of the 
gene (alleles) are active and contribute to the genetic trait.1 This gene locus was 
previously called the protease inhibitor (PI) locus and this nomenclature is still used to 
describe the different genotypes linked to mutation in SERPINA1. Over 150 mutations in 
SERPINA1 have been described. The most common, non-disease causing and so-called 
‘normal’ allele is referred to as the ‘M’ allele; the most frequent (>95% of patients with 
A1ATD) disease-associated SERPINA1 mutations, are referred to as ‘S’ and ‘Z’ alleles. 
The Z allele leads to severe disease symptoms and is the most widely studied variant. S 
and Z alleles lead to aberrantly folded α1-antitrypsin and reduced circulating levels of α1-
antitrypsin. Patients with A1ATD can be classified based on their genotype, which can be 
heterozygous (patients who have 2 different SERPINA1 alleles, for example M and Z 
alleles (PI*MZ and PI*MS genotypes)) or homozygous (patients who have 2 identical 
SERPINA1 alleles, for example 2 Z alleles (PI*ZZ genotype)) for the disease alleles. 
Each copy of the allele will contribute to the disease phenotype.  
A1ATD predisposes to liver and lung disease (Figure 1), but patients with 
A1ATD might also be affected with asthma, granulomatosis with polyangiitis and 
panniculitis. A1ATD-associated liver disease is the consequence of accumulation of 
misfolded α1-antitrypsin in the ER of hepatocytes leading to ER stress. Currently, no cure 
for severe liver disease exists aside from liver transplantation. In contrast, A1ATD-
associated lung disease is due to the consequence of low or undetectable circulating α1-
antitrypsin levels leading to inadequate proteinase inhibition resulting, for example, in 
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damage to the protective layer in the lung. Additionally, polymers of misfolded α1-
antitrypsin, in particular the Z-type α1-antitrypsin in the circulation and in lung tissue, 
and endoplasmic reticulum (ER) stress in monocytes and neutrophils have a role in the 
inflammation observed in A1ATD-associated lung disease. A1ATD-associated lung 
disease shares many characteristics of emphysema, but the pathology differs. A1ATD is 
also a genetic cause of chronic obstructive pulmonary disease (COPD) and is responsible 
for 1-2% of COPD cases. Moreover, the PI*MZ genotype is a risk factor for the 
development of COPD. Individuals with A1ATD-associated lung disease receive many 
standard therapies that are used for the treatment of COPD, in addition to augmentation 
therapy using human plasma-derived, purified α1-antitrypsin to supplement the low levels 
of active α1-antitrypsin. New therapies that target the misfolding of mutant forms of α1-
antitrypsin, or attempt to correct the underlying genetic mutation are being developed.  
In this Primer, we summarize the epidemiology of A1ATD, discuss the 
pathophysiology of A1ATD-associated lung and liver complications and review current 
research in this field. We also consider existing treatment options for A1ATD and future 
developments that might further improve the outlook for patients with A1ATD. 
 
 [H1] Epidemiology  
A1ATD is a relatively common, disorder2, 3. Although most prevalent in European 
(including Scandinavia, Spain and Portugal) and North American countries, A1ATD 
occurs world-wide. A1ATD has been reported in virtually all racial subgroups studied in 
almost 70 countries in 11 geographic regions around the world 4. The global number of 
individuals with the PI*MS or PI*MZ genotype is 116 million and PI*ZZ, PI*SZ, or 
PI*SS is 3.4 million. The prevalence of A1ATD has been estimated using two detection 
strategies: population-based screening and case reports (also called targeted detection). 
Many population-based screening studies for A1ATD have been performed4, 146, the 
largest two were performed in newborn infants in Sweden and Oregon and estimated a 
prevalence of PI*ZZ of 1 per 1,639 individuals in Sweden (n=200,000) and 1 per 5,097 
individuals in Oregon (n=107,038) 5. Data from one study suggests that approximately 
100,000 individuals in the United States have A1ATD characterized by severely 
decreased serum levels 6. Some targeted detection studies have assessed the prevalence of 
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A1ATD in individuals with several diseases. For example, one study estimated the 
prevalence of severe A1ATD in individuals with COPD as between 0–12%, with a mean 
value of 3.6%. In general, all data regarding the prevalence of A1ATD is likely 
confounded by the method of ascertainment and by general under-recognition of A1ATD 
(see Diagnosis, Screening and Prevention).  
 
[H2] Genetic and environmental risk factors  
A genome wide association study tightly linked circulating α1-antitrypsin levels 
in a general population sample to the SERPINA1 gene cluster7. Also, the detrimental role 
of the exposure to cigarette smoke on the clinical phenotype of A1ATD has been 
demonstrated8. In a Swedish study, all 35-year-old individuals with PI*ZZ had normal 
liver and lung function but smoking frequency was significantly lower among patients 
with A1ATD, compared with controls9. Never-smokers with A1ATD also had abnormal 
chest X rays and lung function10. Nevertheless, the wide spectrum of clinical phenotypes 
associated with A1ATD could be caused by interactions between genetic and 
environmental factors other than SERPINA1 and smoking alone. Indeed, single studies 
have identified potential genetic modifiers of COPD phenotypes in patients with severe 
A1ATD. For example, genetic variations in MMP1/MMP3 and TNF have been associated 
with air transfer and chronic bronchitis, respectively, in patients with A1ATD11, 12 and 
polymorphisms in IL10, CHRNA3 and IREB2 are associated with lung function in 
individuals with the PI*ZZ genotype13, 14. The expression of the lung disease for example, 
ranges from asymptomatic to severe emphysema in individuals with PI*ZZ. This 
heterogeneity is likely the result of genetic predisposition to lung disease and some 
environmental factors. For example, interplay between cigarette smoke-induced oxidative 
stress and Z-type α1-antitrypsin polymerization can impact on cellular inflammation and 
cytokine expression15. Regarding the role of the environment on A1ATD few data are 
available suggesting that outdoor air pollution can worsen respiratory status and predict 
lung function decline in individuals with PI*ZZ 16, 17. Another study revealed a 
significant interaction (P<0.0001) between the PI*MZ genotype and high levels of 
exposure to vapours, gases, dusts and fumes on annual change in FEF25–75% levels18. A 
separate study noted a significant interaction (P=0.03) between high-level vapours, gases, 
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dusts and fumes and annual changes in FEV1/FVC17. Overall, larger annual declines in 
lung function in PI*MZ carriers, compared to individuals with PI*MM was associated 
with outdoor particulate matter of ≤10 µm and FEF25-75% decline associated with 
vapours, gases, dust and fumes was observed only in ever smokers with the PI*MZ 
genotype18. Unlike smoking19, environmental or passive tobacco smoke exposure is not a 
risk factor for PI*MZ individuals18.  
 
[H1] Mechanisms/pathophysiology  
The misfolding and accumulation of mutant forms of α1-antitrypsin within the ER 
of α1-antitrypsin-producing cells can lead to toxicity; this primarily affects the liver and 
to a lesser extent the lungs. The accumulation of misfolded α1–antitrypsin causes cellular 
damage through two principal mechanisms; the perturbation of homeostasis within the 
lumen of the ER and the assembly of polymers (especially of Z-type α1-antitrypsin) in 
the circulation, lumen of the lung or within tissues that can cause chemotaxis and/or 
activation of inflammatory cells20. Retention of mutant α1-antitrypsin in α1-antitrypsin-
producing cells leads to low or undetectable α1-antitrypsin levels, which can cause 
defects in other tissues owing to a lack of proteinase inhibition, especially in the lung.  
 
[H2] Genetic basis of disease  
α1-antitrypsin is encoded by the SERPINA1 gene (Figure 2). Different α1-
antitrypsin transcripts are generated in different tissues owing to different transcription 
initiation sites, alternative splicing of untranslated exons 21-23 and tissue-specific 
proinflammatory cytokines in particular IL-6 and leukaemia inhibitory factor and the 
acute phase mediator oncostatin-M24-28. A specific quantitative reverse-transcriptase PCR 
test has been developed to quantify the expression of the different SERPINA1 transcripts, 
to improve understanding of the regulatory mechanisms controlling SERPINA1 
expression29.  
The SERPINA1 gene is highly polymorphic and mutations in this gene cause a 
hereditary co-dominant autosomal disorder. Pathological SERPINA1 α1-antitrypsin 
variants are classified as either ‘deficient' or ‘null’. Deficient variants occur as a result of 
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a point mutation that causes retention of the α1-antitrypsin protein in hepatocytes and 
other α1-antitrypsin-producing cells, resulting in low levels of α1-antitrypsin in plasma. 
Null mutations generally occur due to the presence of a premature stop codon and 
patients with these mutations have no detectable α1-antitrypsin in serum. The most 
common severely deficient variant is Z-type α1-antitrypsin and is caused by a single 
nucleotide polymorphism (SNP) in SERPINA1 that results in the substitution of glutamic 
acid for lysine at residue 342 (Glu342Lys, reference SNP cluster ID (rs)28929474), 
which is found at a frequency between 2–5% in Caucasian individuals of European 
descent. At least 40 other deficient variants have been identified over the last few 
decades; these variants are rare, the molecular mechanism by which they cause disease 
varies and they can be prognostic for either liver and lung diseases30, 31. Similarly, up to 
34 null alleles have been characterized to date32, most of which are extremely rare.  
 
 [H2] Mutant α1-antitrypsin  
α1-antitrypsin’s primary target protease is neutrophil elastase, but it can also 
inhibit other proteases. α1-antitrypsin uses the characteristic serpin inhibitory mechanism 
to irreversibly inhibit the activity of neutrophil elastase 33.  
The Z-type of α1-antitrypsin is retained within the ER of hepatocytes as ordered 
polymers that become sequestered in inclusions, which are Periodic Acid Schiff-positive, 
diastase-resistant on histological examination 34, 35. This same process underlies the 
severe α1-antitrypsin plasma deficiency and intrahepatic inclusions of other protein 
variants of α1-antitrypsin; Siiyama (Ser53Phe)36, Mmalton (∆Phe52)37, and King’s 
(His334Asp)35. Polymerisation also underlies the deficiency of the mild S (Glu264Val), I 
(Arg39Cys), Queen's (Lys154Asn) and Baghdad (Ala336Pro)38 alleles of α1-antitrypsin. 
However the rate of polymer formation, which is proportional to the destabilising effect 
of the mutation on the protein39, is much slower for the I, S, Queen’s and Baghdad 
alleles and explains the absence of liver disease and the association with only mild 
plasma deficiency.  
The initial description of the polymers of Z-type α1-antitrypsin described a 
linkage between the reactive centre loop and β-sheet A on adjacent Z-type α1-antitrypsin 
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proteins34 (Figure 3a). Alternative linkages of α1-antitrypsin polymerisation have been 
described in the crystal structures of a dimer of antithrombin (linkage by a β-hairpin of 
the reactive centre loop and strand 5A (Figure 3b) 40) and a trimer of α1-antitrypsin 
(linkage by strands 1C, 4B and 5B (Figure 3c))41 . The biophysical characteristics of 
polymers of α1-antitrypsin formed by refolding following denaturing by guanidine 
supports the β-hairpin and β-sheet A linkage42. Data from small-angle X-ray scattering 
suggests that trimers, tetramers, and pentamers of Z-type α1-antitrypsin all form ring-like 
structures, consistent with a linkage by strands 1C, 4B and 5B (Figure 3d)43. In patients, 
ring-shaped polymers of α1-antitrypsin are rarely seen in inclusions from the livers of 
individuals with PI*ZZ 34.  
 
[H2] Antitrypsin deficiency 
Mutation in SERPINA1 results in enhanced neutrophil elastase activity, which 
causes a plethora of effects that can contribute to the pathophysiology of A1ATD-
associated lung disease. Enhanced neutrophil elastase activity has a range of 
consequences that lead to inflammation and an enhanced rate of neutrophil reactive 
oxygen species production (Figure 4). Excessive cleavage of molecules involved in the 
immune response (complement factors, immunoglobulins, antimicrobial peptides 44 and 
cell surface receptors such as C-X-C chemokine receptor type 1 (CXCR1) and monocyte 
differentiation antigen CD1445, 46), result in a decreased activation of monocytes (owing 
to reduced responsiveness to lipopolysaccharide (LPS)) and a decreased efficiency of 
phagocytosis by neutrophils — one of the hallmarks of acute inflammation. Reduced 
expression of low affinity immunoglobulin γ Fc region receptor type III-B on the 
neutrophil surface and increased chemotaxis of neutrophils in response to IL-8 and 
soluble immune complexes 47, together with degranulation of secondary and tertiary 
granules further exaggerates the production of reactive oxygen species48. Increased 
cleavage of coagulation factors and extracellular matrix or connective tissue molecules 
(elastin49, collagen50, fibronectin51 and proteoglycans52), can also contribute to the 
pathology. Interestingly, neutrophil elastase can also induce gene expression of ECM 
modulators (matrix metalloproteases and cathepsins) by activation of disintegrin and 
metalloproteinase domain-containing protein 17 (ADAM17) and meprin A-mediated 
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epidermal growth factor receptor (EGFR) signalling53-56. Inactivation of tissue inhibitors 
of metalloproteases57, secretory leucoprotease inhibitor (SLPI)44, elafin58 and cystatin-C59 
has also been reported. Other outcomes that occur either directly or indirectly due to 
decreased α1-antitrypsin levels in the lung, include goblet cell (mucus-secreting cells) 
hyperplasia, increased mucus secretion and impaired mucociliary clearance leading to 
defective bacterial clearance.60 Moreover, reduced inhibition of caspase-3 can promote 
apoptosis of lung endothelial cells61. Emerging data have also indicated that leucotriene 
B4 production, and leukotriene B4 receptor 1 (BLT1) membrane receptor expression62 
are increased in neutrophils, as are tumour necrosis factor (TNF)-α-mediated peripheral 
blood neutrophil apoptosis63. Other evidence has demonstrated increased phosphorylation 
of p38 mitogen-activated protein kinases and NFκB inhibitor α (IκBα), and induction of 
matrix metalloproteinases and cytokines via serine/threonine-protein phosphatase 2A64. 
 
[H2] Accumulation of α1-antitrypsin in ER  
 
[H3] Intracellular disposal mechanisms for misfolded α1-antitrypsin. The retention 
of some protein variants, such as the Z-type α1-antitrypsin in hepatocytes is the inciting 
event in the pathophysiology of A1ATD-associated liver disease (Figure 5)65 and leads to 
apoptosis and oxidative stress of hepatocytes. In healthy cells, misfolded proteins 
accumulated in the ER are degraded by the ubiquitin proteasome system — a process 
called ER-associated protein degradation (ERAD) — or by macroautophagy. In A1ATD, 
the increased load of misfolded protein in the ER causes excessive activation of these 
cellular disposal mechanisms. Soluble Z-type α1-antitrypsin is monitored in the ER and 
diverted to the ERAD pathway, whereas Z-type α1-antitrypsin polymers are degraded by 
macroautophagy. Much of the work investigating handling of misfolded α1-antitrypsin 
has concentrated on the Null Hong Kong (NHK) variant of α1-antitrypsin. The ERAD 
pathway is the major pathway for degradation of NHK α1-antitrypsin owing to its 
inability to fold,66 but even polymerogenic mutants of α1-antitrypsin are also targeted for 
degradation by the ERAD pathway, despite having near-native conformations 66, 67. The Z 
variant of α1-antitrypsin folds more slowly than M α1-antitrypsin and can adopt an 
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intermediate conformation; both of these factors might contribute to the targeting of Z-
type α1-antitrypsin to the ERAD pathway35, 68, 69.  
 Glycoproteins (such as α1-antitrypsin) undergo cycles of N-glycan modification 
whilst within the ER. This mechanism acts as a timer to identify proteins failing to fold in 
an appropriate time. Abnormalities in the enzymes involved in this process might have a 
role in α1-antitrypsin misfolding in A1ATD. Experimental overexpression of ER 
mannosyl-oligosaccharide 1,2-α-mannosidase (ERManI), an enzyme that trims mannose 
residues from N-glycans, accelerates degradation of both NHK and Z-type α1-antitrypsin 
variants in vitro 70, 71, whereas inhibition of ERManI stabilises the variants72. 
Interestingly, a less-frequent allele variant of MAN1B1 (encoding ERManI) that is 
associated with reduced ERManI expression has been reported more frequently than 
expected in children requiring transplantation for Z-type α1-antitrypsin associated liver 
disease, suggesting that protein glycosylation has a role in α1-antitrypsin accumulation in 
patients 73.  
Whole organelles (for example, the ER) or large protein aggregates can be 
degraded by macroautophagy. This process involves engulfment of the structures by 
endomembranes that form autophagosomes, which fuse with the lysosome so that the 
contents are hydrolysed and degraded. Both in vitro and mouse models support a role for 
autophagy in the degradation of Z-type α1-antitrypsin66. Treatment of mice used to model 
A1ATD with carbamazepine (an autophagy-enhancing drug) reduces the accumulation of 
Z-type α1-antitrypsin protein in the liver74, 75. It is currently unknown whether 
macroautophagy shows selectivity for ER containing polymers of α1-antitrypsin, or if the 
turnover of ER in general is just increased. 
 
[H3] Endoplasmic reticulum stress. When misfolded proteins accumulate within the 
ER and threaten to precipitate the cell is said to experience ER stress. ER stress triggers 
an unfolded proteins response (UPR) that reduces the influx of nascent proteins into the 
ER and simultaneously reprograms the cell to fold or dispose of the misfolded proteins 
more efficiently (Figure 6). This process involves the detection of ER stress by three ER 
stress sensors 76, 77.  
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The misfolding variants NHK and Saar α1-antitrypsin, which are truncated and 
unable to fold, can trigger the UPR if expressed even at low levels78-83. All newly 
synthesized proteins sequester chaperones (including 78 kDa glucose-regulated protein 
(also known as BiP)) to keep them in a competent state for subsequent folding or direct 
them to the ERAD pathway if folding is impaired. NHK and Saar variants are normally 
efficiently degraded by the ERAD pathway, but if allowed to accumulate will sequester 
large numbers of BiP, leading to ER stress. The mechanism by which ER stress sensors 
are activated is debated. One model suggests the sequestration of BiP by accumulated 
misfolded proteins reduces the level of free BiP, leading to activation of ER stress 
sensors. 84. An alternative model suggests that the ER stress sensors interact directly with 
stretches of misfolded protein85.  
Interestingly, the dramatic accumulation of polymeric α1-antitrypsin does not 
activate the UPR in most circumstances, despite ER stress 82, 83, 86-90. As α1-antitrypsin 
polymers are generally thought to be relatively well-folded structures, they might not 
present misfolded stretches of amino acids and so fail to activate the ER stress sensors. 
However, the accumulation of polymers does seem to sensitize the cell to second insults 
that can cause ER stress83, 86-88. The mechanism for this sensitization is not well 
understood, but might involve altered protein mobility in the ER lumen, either owing to 
local alterations in viscosity or on the degree of ER interconnectivity83. 
Accumulation of α1-antitrypsin polymers can impact on a variety of intracellular 
signalling pathways leading to the transcriptional upregulation of proinflammatory genes, 
including increased basal and LPS-induced expression of IL6 and CXCL8 in monocytes 
derived from patients with Z-type A1ATD, versus non-α1-antitrypsin deficient 
individuals. Upregulation of proinflammatory genes is associated with intracellular 
accumulation of Z-type α1-antitrypsin polymers in monocytes 91. The accumulation of 
polymerogenic α1-antitrypsin triggers nuclear factor κB (NF-κB) signalling, which has 
been termed the ‘ER overload response’. Little is known about this response, but leakage 
of calcium from the ER might have a role in NF-κB activation; chelation of cytosolic 
calcium has been shown to limit the activation of NF-κB88. In contrast, primary bronchial 
epithelial cells expressing low levels of Z-type α1-antitrypsin without polymer formation, 
also showed enhanced basal NF-κB signalling89. This indicates that increased NF-κB 
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signalling is not restricted to activation of the ER overload response. A possible 
alternative mechanism might involve the increased activity of ADAM17. Primary 
bronchial epithelial cells isolated from individuals with PI*ZZ show hyperactive 
extracellular signal-regulated kinase (ERK) signalling, which depends on the activity of 
ADAM17. Moreover, increased ADAM17 activity has been reported on the surface of 
neutrophils of patients with A1ATD.  
 
[H2] Extracellular α1-antitrypsin polymers  
Polymers of α1-antitrypsin can also be detected in the blood92, bronchoalveolar 
lavage fluid and lung tissue of patients with A1ATD 93, 94. It is unclear if most polymers 
are formed by the polymerization of secreted Z-type α1-antitrypsin proteins in the 
extracellular space, because they can also be secreted at low levels by from dying cells95. 
However, most extracellular polymers are of hepatic origin, as the circulating levels of 
these polymers falls to undetectable levels four days after liver transplantation92. α1-
antitrypsin can also be synthesised locally by airway epithelial cells, but at levels too low 
to allow the formation of intracellular polymers89.  
Extracellular polymers of α1-antitrypsin have pro-inflammatory effects. For 
example, they are chemotactic and stimulatory for neutrophils and likely contribute to 
both pulmonary inflammation and the increased incidence of vasculitis or panniculitis 
seen in individuals with the PI*ZZ genotype, following the deposition of these polymers 
in other tissues 96 . 
 
 
[H1] Diagnosis, screening and prevention  
α1-antitrypsin deficiency is a widely under-diagnosed condition. The estimate of the 
mean interval between the development of the first symptom of disease (usually 
dyspnoea (shortness of breath)) and initial diagnosis has not changed over the past 20 
years and ranges from 5.6–8.3 years3, 97. Similarly, the number of healthcare providers 
that patients with A1ATD see before the diagnosis is initially made has not lessened over 
time2. This delay in diagnosis has been associated with adverse psychosocial effects3 and 
delays the implementation of disease management and the identification of family 
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members at risk of A1ATD. Thus, better recognition of this disorder by healthcare 
providers is urgently needed.  
Under diagnosis of A1ATD is supported by three lines of evidence. Firstly, in all 
countries where diagnosis of A1ATD has been examined, only a small minority of the 
actual number of individuals with A1ATD have been diagnosed with this disorder98. 
Secondly, few physicians comply with the American Thoracic Society and European 
Respiratory Society (ATS/ERS) guidelines that state that all patients with COPD should 
be assessed for A1ATD99. Thirdly, patients with A1ATD frequently experience long 
delays and see many healthcare providers between their first symptom and diagnosis of 
A1ATD.  
 
 
 
[H2] Diagnostic tests  
Owing to the heterogeneous clinical presentation, the diagnosis of A1ATD is 
predominantly based on the results of laboratory testing, although clinical features of α1-
antitrypsin deficiency may be useful for selecting individuals for testing (Figure 7). The 
diagnostic test are well established throughout the world and involve the quantification of 
either plasma or serum α1-antitrypsin levels typically performed using a nephelometer, in 
combination with either genotyping or PI typing100. Genotyping usually starts off with the 
detection of the most common disease-associated alleles (Z and S) using genotype-based 
allele specific amplification by qPCR. This genotyping can be performed using DNA 
isolated from dried blood spots, whole blood and saliva and results from this diagnostic 
test dictate what subsequent diagnostic tests are performed (for example, Figure 7) 101. 
Reflex testing, meaning, follow up testing for identification of alleles other than S or Z, is 
usually performed by protease inhibitor typing using isoelectric focusing of serum or 
plasma. Each phenotype of A1ATD displays a characteristic banding pattern on 
isoelectric focusing that can be compared to known reference samples100. Although S and 
Z alleles are present in >95% of all patients with A1ATD, the remaining 5% have rare 
deficiency alleles, such as those associated with reduced, dysfunctional or absent plasma 
α1-antitrypsin levels102. These rare alleles are not detected by routine diagnostic methods, 
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but require a combination of protease inhibitor typing and next generation sequencing of 
SERPINA1 102.  
 
 [H2] Patient selection for A1ATD diagnostic testing 
Three approaches to select individuals for diagnosis testing of A1ATD exist. 
First, the diagnostic testing of individuals with symptoms or signs consistent with 
A1ATD, such as early onset, primarily lower lobe emphysema. In the past, this paradigm 
led to under diagnosis and late diagnosis of A1ATD. Second, predisposition testing of 
those who might be high-risk for A1ATD, such as asymptomatic individuals carrying a 
genetic mutation in SERPINA1 and who have low levels α1-antitrypsin levels and a 
family member with A1ATD. Development of symptoms is likely for these patients, but 
it is not certain. Third, targeted detection in patients with a clinical reason to suspect 
A1ATD. Including, all patients with conditions associated with increased prevalence of 
A1ATD, such as COPD, poorly responsive asthma, cryptogenic liver disease, 
granulomatosis with polyangiitis, bronchiectasis of unknown aetiology and panniculitis, 
in addition to first degree relatives of patients with A1ATD. Targeted detection is similar 
to diagnostic testing but applies the ATS/ERS guidelines for the diagnosis and 
management of patients with A1ATD and has been shown to substantially increase the 
rates of diagnosis103. The use of the ATS/ERS criteria for targeted detection has been 
shown to enrich the detection of A1ATD; the allele frequency for the Z allele was over 
fourfold higher in the targeted population, compared with an unselected sample of the 
general population103. Guidelines regarding the potential benefits of targeted detection 
versus screening should be revisited particularly in lieu of the increased understanding of 
the pathogenesis of A1ATD-associated-disease. 
 
[H2] Screening  
Screening guidelines for A1ATD are dynamic and rapidly evolving. The ATS/ERS 
guidelines do not recommend population-wide neonatal screening for A1ATD 99 (the 
testing of groups without known risk factors). This is based on evidence from a Swedish 
study104, which showed that although neonatal screening reduced parental smoking rates 
following detection of a genetic mutation in SERPINA1, there was an increased incidence 
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of parental distress and a negative impact on the mother–child relationship104. Also, the 
ATS/ERS guidelines do not generally recommend universal screening of adolescents 
aged <11 years, but suggest that screening should be discussed with individuals in areas 
with a high prevalence of A1ATD or if parental smoking rates are high, providing that 
adequate genetic counselling is given. Recommendations for adults are similar to those 
for adolescents99. The ATS/ERS guidelines99 recommend testing high-risk groups, 
including all individuals appropriate for targeted detection.. This screening approach has 
been shown to increase the detection of αA1ATD. 
 
The 2014 Global Initiative for Chronic Obstructive Lung Disease (COPD) 
recommendations105 quote the World Health Organization106, who recommend that 
COPD patients from areas with a particularly high prevalence of α1-antitrypsin 
deficiency should be tested for A1ATD. Also, they noted that individuals with COPD 
with α1-antitrypsin deficiency present with panlobular, lower lobe emphysema (compared 
to centrilobular apical distribution in COPD) at a younger age (<45 years), compared to 
patients with COPD and suggest that family members at risk of α1-antitrypsin deficiency 
should be identified. The Global Initiative for COPD recommendations are not dissimilar 
from those that led to substantial under diagnosis of αA1ATD for the past 50 years.  
  
 
[H2] A1ATD registries  
Data from rare disease patient registries increases awareness and knowledge of 
rare diseases, and is important for supporting both clinical and epidemiological research 
and monitoring of orphan drugs and the use of off-label medications 107. Moreover, these 
registries are important for patients and their families; they provide a beneficial effect on 
health and social services planning and the ability to improve quality of care, quality of 
life and patient survival. According to the European Organization for Rare Diseases, the 
ideal patient registry should be disease-centred, be able to be used in combination with 
other data sets, contain minimum set of common data elements, be sustainable through 
the encouragement of public-private partnerships, should include data from various 
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sources (patients and healthcare professionals) and link with corresponding biobank data., 
Currently, no A1ATD registries exist that meets these criteria. 
The first prospective registry for patients with A1ATD was the National Heart, 
Lung and Blood Institute (NHLBI) Registry which enrolled 1,129 patients with severe 
A1ATD between 1989-1992 and followed them until 1996108. This Registry collected 
information on patient demographics, medical history, measurements of pulmonary 
function and other laboratory evaluations at baseline and at 6-month or yearly intervals 
during follow-up. Data generated from this registry has produced some of the pivotal 
findings on the natural history of A1ATD, patient mortality and problems associated with 
a delayed diagnosis. Also, the effects of α1-antitrypsin augmentation therapy for patients 
was examined, although it was recognized that these results needed to be viewed with 
circumspection as results were not generated from a randomized clinical trial.  
The current Alpha-1 Foundation Research Registry for patients in the US 
commenced enrolment in 1997 and enrolled patients with mildly-deficient genotypes 
between 1997-2002109. This registry is a contact registry, allowing appropriate patients 
with A1ATD to receive invitations to participate in clinical trials, although plans are to 
enlarge the remit of this registry. An Alpha One International Registry was also founded 
in 1997, which aims to establish an international database of patients with A1ATD to 
collect data on demographics, to promote and coordinate basic and clinical research into 
α1-antitrypsin deficiency, to collect, assess and disseminate information regarding 
different aspects of α1-antitrypsin deficiency and also, to raise support and awareness of 
α1-antitrypsin deficiency. The Alpha One International Registry now includes almost 
twenty European and non-European countries110. There is only one inclusion criterion for 
the international registry, in that the patients must have a PI*ZZ, PI*SZ or other severely 
deficient phenotype. Some patients (for example patients in certain national registries) 
received annual follow up to collect information allowing the documentation of disease 
characteristics, treatments, in addition to the smoking habits and lung and liver function 
of patients. There are also other large non-affiliated registries for α1-antitrypsin 
deficiency103, 111.  
 
[H2] Prevention  
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There are compelling reasons to identify patients with A1ATD early, for example 
to allow patients access to specific therapies and improve opportunities to avoid the 
environmental triggers of lung disease, including by the avoidance of personal and 
passive cigarette smoking112-114.  
Personal cigarette smoking is associated with a considerable reduction in the life 
span of patients with A1ATD 115 and one study has shown that never-smokers with 
A1ATD might have normal life spans115. Importantly, patients with A1ATD who have 
developed COPD do so following exposure to a much lower number of pack-years of 
cigarette smoking, compared with individuals with COPD in the absence of A1ATD. 
The early identification of α1-antitrypsin deficiency in neonates, adolescents and 
adults is associated with a reduction in the number of patients electing to start smoking 
with lower addiction rates as a consequence, and also, an increase in smoking cessation 
rates116, 117. For these reasons, counselling on the avoidance or cessation of smoking 
should be the number one focus for physicians and health care providers following the 
identification of α1-antitrypsin deficient patients of any age. 
In addition to exposure to cigarette smoke, some occupational exposures such as 
mineral dust and certain fumes are associated with increased impairments in lung 
function and symptoms of respiratory disease in patients with A1ATD 118. 
Modifiable risk factors for liver disease are less well understood, but obesity is 
known to increase the risk. In addition, males are more at risk of liver disease, compared 
to females119. Current recommendations for patients with A1ATD include vaccinations 
for hepatitis A and B and moderate alcohol consumption and a healthy diet in individuals 
with PI*ZZ 112.  
 
[H2] Monitoring A1ATD-associated complications  
 
[H3] Monitoring lung complications. Spirometry (lung function tests) typically seen in 
patients with A1ATD who have emphysema include a reduced forced expiratory volume 
in 1 second (FEV1), reduced FEV1/forced vital capacity ratio, air trapping (raised residual 
volume/total lung capacity ratio) and a low diffusion capacity. A partial reversibility of 
the airflow obstruction (as defined by an increase of 12% or 200 ml in FEV1 after a 
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bronchodilator) is common in individuals with COPD secondary to A1ATD. Beyond this 
CT is a good parameter for lung diagnsosis and has been used in various A1ATD 
augmentation therapy trials.  
 
[H3] Monitoring liver complications. Many authorities, such as the American Associated 
for the Study of Liver Disease, suggest regular monitoring (at least once per year) of 
patients with A1ATD for the development of liver disease, by a physician familiar with 
liver disease and associated complications120. Monitoring should include history and 
physical examination sensitive for liver disease, such as focusing on the detection of 
splenomegaly, and laboratory assessment of white blood cell count, platelet count, levels 
of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, albumin, 
bilirubin and assessment of the international normalized ratio. Progressive liver disease is 
often accompanied by granulocytopenia, thrombocytopenia and elevated liver enzymes 
and bilirubin and coagulopathy. As with the detection of other liver diseases, a baseline 
liver ultrasonographyis often considered useful and is recommended every 6 months for 
patients at increased risk (>2% per year) hepatocellular carcinoma, in guidelines issued 
by the American Associated for the Study of Liver Disease (AASLD) 121. Although data 
for the risk of hepatocellular carcinoma in α1-antitrypsin deficiency is lacking, the 
AASLD guidelines should be applied to patients with to A1ATD with evidence of 
cirrhosis, portal hypertension or persistently large elevations of liver tests.  
 
 
[H1] Management  
[H2] Lung disease 
 The 2011 Global Initiative for COPD (GOLD) strategy can identify patients with 
A1ATD at increased risk of poorer outcomes from lung disease, specifically focusing on 
mortality, lung function decline and exacerbations122. In the Swedish registry of 
individuals with PI*ZZ, respiratory symptoms were the most common presenting feature 
A1ATD (in 43% of patients) and respiratory disease was the most common cause of 
death (55% of patients)10. The presence of lung disease is dependent on the smoking 
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history of the patient; in never-smokers 28% of patients fulfilled spirometric criterion for 
COPD, which rose to 72% in ex-smokers.  
The rationale for the treatment of α1-antitrypsin deficiency-associated lung disease is to 
increase the levels of α1-antitrypsin in the lung towards levels seen in healthy individuals 
(that is, augmentation therapy), thus reversing the lack of inhibition of neutrophil elastase 
and other proteases, which, when uninhibited, can cause emphysema. Initially, 
augmentation therapy was performed by the intravenous delivery of plasma-purified α1-
antitrypsin to patients123, which resulted in increased levels of α1-antitrypsin and 
increased inhibition of neutrophil elastase both in serum and on the pulmonary epithelial 
surface. Data from a number of clinical trials have shown a clinical benefit of the use of 
augmentation therapy for the treatment of A1ATD (Table 1). Augmentation therapy is 
usually commenced with evidence of lung disease (usually equating to a decreased 
FEV1and is administered once per week as intravenous infusions.  
Concerns about the purity of human plasma-derived purified α1-antitrypsin and 
the transmissibility of infection has led to the evaluation of transgenic and recombinant 
sources of α1-antitrypsin. Recombinant α1-antitrypsin has been successfully produced in 
bacteria, yeast and transgenic sheep (engineered to produce α1-antitrypsin in their milk), 
but; these recombinant proteins have lack of, or abnormal glycosylation, which causes 
altered renal clearance and a short half-life following intravenous administration124. 
Clinical trials investigating the use of an inhaled, recombinant form of α1-antitrypsin that 
has an appropriate pulmonary half-life are currently underway. Also, aerosolization of 
plasma-purified α1-antitrypsin and recombinant α1-antitrypsin is effective at delivery to 
both the alveolar surface and alveolar interstitium, but whether the amount of α1-
antitrypsin is of sufficient quantity for clinical efficacy has not yet been evaluated125, 126.  
Other treatments for A1ATD-associated lung disease include therapeutics 
commonly used for the management of COPD, including short-acting and long-acting 
beta adrenergic receptor agonists, muscarinic receptor antagonists (anticholinergics), in 
addition to influenza and pneumonia vaccination  
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Currently, there is no specific treatment for α1-antitrypsin liver disease and 
treatments for progressive liver injury are primarily supportive and focus on preventing 
malnutrition, rickets, and managing the complications of portal hypertension such as 
ascites or variceal bleeding. Patients with A1ATD-associated cirrhosis can remain stable 
with compensated disease and minimal signs and symptoms for years 127. In these 
patients, the detection of cirrhosis with portal hypertension is critical, so the patient can 
be cautioned against the development of splenic injury from playing contact sports, 
advised to abstain from alcohol, undergo surveillance for variceal bleeding, and 
cautioned to avoid the use of NSAIDS. Consumption of NSAIDs in patients with portal 
hypertension can result in life-threatening bleeding, even in well-compensated patients. 
There are no data regarding alcohol consumption in individuals with PI*ZZ who have no 
evidence of liver injury. AASLD guidelines for adults with hepatitis C without evidence 
of liver injury suggest that up to three alcoholic drinks per week may be safe. 
For life-threatening, progressive liver failure or uncompensated cirrhosis, liver 
transplantation is the only therapeutic option. In the United States, patients at the highest 
need for liver transplant are classified by empirically derived severity scores for both 
children and adults, which are correlated with an increasing risk of mortality without 
transplant. The early evaluation at a transplant centre is recommended for patients with 
signs or symptoms of deteriorating liver function, although in the United States neither 
early addition to the transplant wait list or the time spent on the list influence the severity 
scores. In other countries, wait lists and liver transplantation is highly variable and is 
often influenced by time to referral, waiting and centre-specific factors. Many transplant 
centres have reported excellent liver transplant outcomes for α1-antitrypsin deficiency 
and outcomes are often better in α1-antitrypsin deficient patients, compared to those with 
other liver diseases; 1-year survival rates are 73% in adults and 87% children, dropping 
to 60% and 83%, respectively at 5 years 128. In addition to cadaver-based donor 
transplantation, living donor liver transplants in infant (using a donated left lateral 
segment of the liver) and adult (using a split liver donation) patients with A1ATD are 
also successful, including surgeries performed using a donor liver from a patient with 
PI*MZ129. Complications of liver transplantation include hepatic artery thrombosis, 
portal vein thrombosis, severe graft dysfunction, sepsis, intraoperative death, 
21 
 
lymphoproliferative disease, chronic rejection, biliary complications. Death from liver 
transplanatation occur primarily in the first six months , most often due to hemorrhage, 
infection , or graft failure ~ 5-10%.  
 
 [H1] Quality of life  
 
[H2] Life expectancy  
A1ATD can both shorten survival108, 115, 130-133 and can compromise patients 
quality of life (QOL)(Table 2)134.  
A1ATD is associated with considerable morbidity and mortality135. The median 
age at death for smokers with severe A1ATD is estimated at 40 years 115 and in a separate 
study, the cumulative survival up to age 50 was 52% 132. In the largest available 
longitudinal study from the National Heart, Lung and Blood Institute Registry of 
Individuals with A1ATD 108, the mortality rate was approximately 3% per year for 
patients with α1-antitrypsin deficiency (in which most of the subjects were either current 
(8%) or ex-smokers (72%)) .  
FEV1 is a major correlate of mortality in α1-antitrypsin deficiency and patients 
entering the National Heart, Lung and Blood Institute Registry with an FEV1>50% had a 
normal expected survival, whereas patients with a baseline FEV1<15% had a 3-year 
mortality rate of 36%133. In a Danish Registry of 347 patients, the median survival of 
patients with a FEV1<25% was 6.3 years but increased for patients with FEV1>25% (10.5 
years) and FEV1>50% (14.2 years)130. FEV1136 and thoracic CT densitometry137, are both 
important predictors of patient survival, with a more rapid deterioration associated with 
the patient being a current smoker, aged between 30–44 years, of male sex, a predicted 
FEV1 between 35–60% and a history of asthmatic features, chronic bronchitis and 
episodes of pneumonia136, 138. 
COPD is less prevalent and patient survival is longer in never-smokers with 
A1ATD. For example, the median age at death of never smokers with COPD and 
A1ATD has been estimated as 65 years, versus 40 years for patients with COPD and 
A1ATD who smoked115. Also, never-smoking individuals with PI*ZZ who were 
asymptomatic had a normal lifespan (odds ratio for death = 0.7 compared with age- and 
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gender-matched peers)131. Other factors contributing to prognosis of patients with 
A1ATD include the initial reason that prompted diagnosis of A1ATD, for example, the 
standardized mortality ratio for ptients with A1ATD is highest (5.0) in patients who are 
diagnosed following the development of liver symptoms131. 
The most frequent cause of death among patients with A1ATD is COPD or 
sequelae133, including malignancy (not HCC), diverticulitis, sepsis and/or infection and 
trauma. In the NHLBI Registry, emphysema accounted for 72% of deaths and cirrhosis 
for 10% in all patients with A1ATD133, whereas among PI*ZZ never smokers, 
emphysema accounted for fewer deaths (45%) but liver disease for more (28%)131. 
 
[H2] Associated complications and quality of life  
A1ATD also contributes to substantial morbidity and impaired QOL. As with 
patients with COPD, patients with A1ATD-associated COPD experience depression 
(25%), clinically relevant anxiety (36%), dyspnoea and impaired health-related QOL 139. 
The number of patients with anxiety and depression was similar among patients with 
COPD with or without A1ATD, but dyspnoea was more common in patients with 
A1ATD(assessed using the Modified Medical Research Council Dyspnea Scale) and so 
was their health-related QOL (based on the St. George’s Respiratory Questionnaire 
(SGRQ)). In a series of 1062 individuals with severe A1ATD134, those >59 years of age 
experienced fewer exacerbations and had better QOL scores (SGRQ and the Short Form 
(36) Health Survey) than younger individuals.  
Healthcare-related QOL improved in patients with A1ATD receiving 
augmentation therapy following participation in a disease management program, 
consisting of directed patient self-education (with a comprehensive reference guide 
describing COPD and A1ATD) and organized supervision (monthly telephone 
conversations with A1ATD program coordinators, supervising participants’ 
understanding of their long-term treatment plans) 140. Participation in disease 
management programs was also associated with a 1-year improvement in medication 
adherence, enhanced compliance with supplemental oxygen and reductions in the use of 
some healthcare resources (though not overall hospitalization rates)140. However, 
although augmentation therapy alone has not been shown to improve health-related 
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quality of life measures, despite slowing the progression of emphysema and 
exacerbations141, 142.  
 
[H1] Outlook  
The reasons why the clinical presentation of disease in individuals with Pi*ZZ is 
so variable, remain unclear, but this might, in part, be due to the contributions of genetic 
modifiers, such as MAN1B173. The use of iPSCs from patients with A1ATD and severe 
liver disease143, 144, which show delayed clearance of Z-type α1-antitrypsin and have a 
more prominent accumulation of inclusions when differentiated into hepatocytes, 
combined with whole genome analysis would allow characterization of these differences 
and is likely to clarify the effect of genetic modifiers and help to identify patients more 
likely to develop liver disease. 
 
[H2] Augmentation therapy  
Augmentation therapy with purified α1-antitrypsin is not universally accepted for 
the prevention of emphysema in patients with A1ATD, although recent trials using 
surrogate endpoints, such as CT lung density measurements, for lung protection have 
been encouraging141, 142, 145. On balance, most evidence supports the efficacy of 
augmentation therapy in slowing the progression of emphysema in patients with A1ATD. 
Augmentation therapy has some downsides, namely, that the treatment is expensive and 
requires repeated, lifelong, intravenous infusions. Moreover, the estimate of the level of 
plasma α1-antitrypsin required to protect against emphysema (11µM) is arbitrary and was 
based on the not fully proven hypothesis that PI*SZ patients who do not smoke do not 
have an increased risk for COPD. The optimal dose of augmentation therapy has yet to be 
determined, as patients receiving augmentation therapy lose some of the 
immunomodulatory effects of α1-antitrypsin just before they receive their next infusion. 
Also, one study conducted in 2015 (RAPID study) suggested that higher doses of α1-
antitrypsin resulted in less lung density decline, observed using CT, compared with lower 
doses. Also, the full mechanism of the protective action of augmentation therapy is 
currently unknown; if the effect of α1-antitrypsin is solely mediated by correction of the 
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protease-antiprotease balance, or if the beneficial effects are evident primarily due to 
modification of inflammation requires further research. 
 
[H2] Emerging therapies  
Many new approaches are currently being examined for their use in the treatment of 
A1ATD. Extensive studies have been published using in vitro analyses of molecular 
structure of α1-antitrypsin and >10 different compounds have been shown to block liver 
injury in the PiZ mouse model (transgenic mice expressing the human Z-type α1-
antitrypsin) of α1-antitrypsin liver disease, although none have been approved for human 
use 74, 146, 147.  
 
[H3] SERPINA1 silencing. Therapies that target the synthesis of Z-type α1-antitrypsin, 
aiming to prevent the accumulation of these proteins and subsequent liver injury are 
currently being examined through the application of RNA inhibition technology. 
Preclinical data obtained from the PiZ mouse model showed the complete reversal of the 
liver injury following the delivery of SERPINA1 small interfering RNAs (siRNA) 148. 
Alnylam are undertaking a Phase I clinical trial examining the safety of siRNA-mediated 
inhibition of the Z-type α1-antitrypsin synthesis as a therapy for liver disease. One of the 
major caveats associated with the use of SERPINA1 siRNA , is that this would prevent all 
α1-antitrypsin production, which could cause further lung damage. To counteract this, 
patients receiving α1-antitrypsin siRNA will require supplementation using, for example, 
transfection with the normal gene (using, for example, viral vector-mediated gene 
therapy) and/or augmentation therapy. 
 
[H3] Intracellular degradation of Z-type α1-antitrypsin. Methods to accelerate the 
intracellular degradation of Z-type α1-antitrypsin as a treatment for liver disease have 
also been assessed. Data from in vitro and mouse model experiments have shown that 
enhanced macroautophagy can reduce the burden of Z-type α1-antitrypsin in the liver and 
also reduce liver injury74, 146, 147. Drugs that enhance autophagy, such as sirolimus (also 
known as rapamycin), carbamazepine, and the bile acid 24-norursodeoxycholic acid 
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(norUDCA), in addition to a genetic approach used to augment expression of key 
autophagy regulators, have all been shown to reduce Z-type α1-antitrypsin accumulation 
in hepatocytes and to reduce liver cell injury in a mouse model system 74, 146. However, 
excessively high doses of all of these agents were required to show an effect. A phase II 
clinical trial assessing low dose carbamazepine in patients with PI*ZZ-associated 
cirrhosis is currently underway, although results to date have been inconclusive 
(NCT01379469).  
 
[H3] Improving α1-antitrypsin folding. Other studies have focused on the use of 
chemical chaperone approaches to improve correct folding of α1-antitrypsin and to 
augment the secretion of Z α1-antitrypsin instead of retention in the liver (Figure 5). 
These approaches might be able to treat both the lung and the liver, however; the primary 
barrier to this is the large volume α1-antitrypsin protein that is synthesized per day. If a 
1:1 binding stoichiometry is needed for efficacy of these drugs a large concentration of 
drug would need to be delivered to hepatocyte ER, which might prove clinically difficult. 
Nonetheless, in vitro studies have shown that several compounds promote the secretion 
of Z α1-antitrypsin and one of these compounds, 4-phenylbutyrate (4PBA), was also 
effective in a mouse model149. Following on from these studies, a pilot trial was 
conducted in patients, which showed no effect on α1-antitrypsin secretion150. Results 
from this trial are likely explained due to the inability of drug levels to reach the 
therapeutic range in patients, as those documented in the mouse model150.  
Protein folding systems found within different cellular compartments are highly 
intertwined 151 and data from some studies suggest that targeting maladaptive protein 
folding responses in the cytosol can improve the folding of substrates in the ER, 
including Z α1-antitrypsin152. One studyhas identified the histone deacetylase 7 inhibitor 
suberoylanilide hydroxamic acid as molecule that can restore Z α1-antitrypsin secretion 
from epithelial cells153.  
 
[H3] Inhibiting α1-antitrypsin polymerization. Strategies designed in silico or using cell 
free systems for the therapeutic disruption of Z-type α1-antitrypsin polymerization, 
26 
 
(likely an event separate to the protein retention signal), have also been examined 147, 154. 
These largely peptide-based approaches aim to modulate the conformational behaviour of 
α1-antitrypsin by targeting it directly to fold correctly, stabilize functional conformers and 
limit the population of polymerogenic intermediates155-161. However, many of these 
compounds had an aberrant effect following examination in vitro and there have been 
difficulties into creating medicinal molecules for use in animal models. Moreover, 
compounds sharing a similar structure to the reactive loop of α1-antitrypsin (reactive loop 
analogues) can generate complexes with α1-antitrypsin that do not show antiprotease 
activity. Nonetheless, these molecules could still have potential for the treatment of α1-
antitrypsin accumulation in hepatocytes. 
 
 
[H3] M-type α1-antitrypsin synthesis. Finally, several studies that have progressed to 
evaluation in clinical trials, have evaluated strategies to synthesize M-type α1-antitrypsin 
in tissues outside the liver, which might then lead to an increase in serum levels to protect 
patients from lung, but which would not change the risk of liver injury162, 163. However, to 
date, these studies have only been able to generate less than 5% of the serum M-type α1-
antitrypsin level thought to be needed for a therapeutic benefit in humans using an adeno-
associated vector carrying SERPINA1 163. Various gene therapy approaches have been 
designed to increase the levels of circulating α1-antitrypsin with one having reached 
Phase II testing163-168. Two of these approaches involve haematopoietic stem cell therapy, 
coupled with delivery of lentiviral vector containing SERPINA1169, 170 or intrapleural 
administration of a replication-deficient adeno-associated viral vector containing the 
SERPINA1 transgene171.  
Other future potential treatments include the use of induced pluripotent stem cells 
143, 172, 173 generated from skin fibroblasts harvested from individuals with PI*ZZ, then 
reprogrammed to form hepatocyte-like cells that still possess the A1ATD phenotype143. 
Using the CRISPR-CAS9 system to correct the Z mutation in these cells172 could 
generate PI*MM cells, that share the characteristics of those found in healthy individuals. 
Theoretically, these cells could be used for autologous grafting without the risk of 
immune rejection. In vitro reports using this technique are still limited and no clinical 
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trials have been commenced, however; this approach is still promising and might be a 
long term answer to the treatment of both lung and liver disease manifestations of this α1-
antitrypsin deficiency.  
  
 
[H2] Other disorders 
α1-antitrypsin is one member of a large family of serine protease inhibitors, 
known as serpins. Other members of this protease family are mutated in human diseases 
and so it is likely that data obtained from the study of α1-antitrypsin will have wider 
biomedical application. For example, mutant forms of the neuron-specific serpin 
(neuroserpin) also undergoes polymerization and formation of inclusion bodies in the 
same way as α1-antitrypsin, but accumulation of mutant neuroserpin leads to 
neurodegeneration and early onset dementia174. The development of therapeutics that 
prevent the polymerization of α1-antitrypsin will also rapidly lead to the development of 
therapies for other serpinopathies that are primarily associated with accumulation of 
polymers. Similarly, the development of small molecules designed to mimic the anti-
inflammatory effects of α1-antitrypsin would be applicable for use in other disorders, 
since α1-antitrypsin augmentation therapy has been shown to be beneficial in other 
diseases, including cystic fibrosis175, 176. 
Finally, the mechanism by which accumulation of polymers of α1-antitrypsin in 
the lumen of the ER can trigger downstream signalling is unknown, but it has been 
proposed that the ER overload seen in this condition, might also mediate cellular 
responses to enveloped viruses. The study of α1-antitrypsin is highly important and could 
improve knowledge of other more prevalent conditions177, 178.  
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Figure legends 
Figure 1 | Clinical manifestions of PI*ZZ. About 15% of infants with PI*ZZ 
genotype have or develop clinical relevant liver disease. The clinical symptoms of 
jaundice typically resolve by the second year of life but can progress to cirrhosis in 15% 
of children who had jaundice at birth5, 179. The risk of death from liver disease in children 
with PI*ZZ is between 2-3%180, 181. Serum aminotransferases and bilirubin levels 
(markers for liver dysfunction) are raised in 70% and 11% of infants, respectively, in 
their first year of life but the levels typically go down. Raised aminotransferases remain 
abnormal in 15% of patients by 12 years of age and serum bilirubin levels fall to within 
the normal range by 6 months of age. Some adults with Z-type A1ATD have slowly 
progressive hepatic damage that is asymptomatic and is only apparent as a minor degree 
of portal fibrosis. A1ATD-associated cirrhosis  can present in adults of any age.  13% of 
patients with PI*ZZ die from liver disease10. Lung dysfunction develops between the 
third and fourth decade of life. Emphysema associated with Z-type A1ATD is typically 
panlobular and affects the bases of the lungs. Patients initially present with breathlessness 
and cor pulmonale (enlargement of the right side of the heart owing to lung disease) and 
polycythaemia (increased red blood cell levels in the blood can occur late in the disease99. 
PI*ZZ A1ATD is also associated with an increased prevalence of asthma182, 
panniculitis183 and granulomatosis with polyangiitis184. The underlying disease 
mechanisms are currently unknown but pro-inflammatory polymers of Z α1-antitrypsin 
and deficiency of M-type α1 antitrypsin might contribute to both granulomatosis with 
polyangiitis and panniculitis. 
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Figure 2 | SERPINA and α1-antitrypsin. A | SERPINA gene, which encodes α1-
antitrypsin, is located on the long arm of chromosome 14 at 14q32.1. The gene consists 
of four coding exons (II, III, IV, and V), three untranslated exons (Ia, Ib, and Ic) and six 
introns. Distinct promoters and transcription start-sites in the 5′-untranslated region (5′-
UTR) have been identified for hepatocytes and extra-hepatic tissues such as 
monocytes/macrophages and the cornea21. The hepatocyte SERPINA1 promoter is located 
within exon 1C, upstream of the hepatocyte transcription start site21, 185. Alternative 
promoter regions are located upstream of exon 1A and before exon 1B; these control 
SERPINA1 expression in monocytes and macrophages21, 186. The most common A1ATD-
associated mutation are depicted. B| The α1-antitrypsin protein is a 394 residue, 52 kDa 
glycoprotein that is synthesised by hepatocytes, lung and gut epithelial cells, neutrophils 
and alveolar macrophages. Structure of monomeric α1-antitrypsin with the position of key 
mutations shown in black α1-antitrypsin contains a ‘reactive loop’, which contains a 
neutrophil elastase binding site. Neutrophil elastase docks with, then cleaves the reactive 
loop of α1-antitrypsin, which causes the translocation of elastase from the upper to the 
lower pole of α1-antitrypsin, and irreversibly inhibits the activity of the enzyme33.  
 
Figure 3. Proposed models of serpin polymerisation (key linkage motifs highlighted in 
black): i. Reactive centre loop- β-sheet A linkage, ii, linkage by a β-hairpin of the 
reactive centre loop and strand 5A and iii, linkage with strands 1C, 4B and 5B. Figure 
generated with PyMol by Dr James Irving, UCL, UK.  
 
Figure 4. Intrapulmonary consequences of unopposed neutrophil elastase activity. 
Neutrophil elastase is normally inhibited by α1-antitrypsin. However, in the lung of 
A1ATD patients, unopposed neutrophil elastase activity can activate cell surface 
receptors and transcriptionally upregulates expression of classes of genes. 
 
Figure 5 | Accumulation of misfolded α1-antitrypsin in hepatocytes. Misfolding of α1-
antitrypsin leads to α1-antitrypsin accumulation in the ER, which either gets degraded via 
the ERAD pathway or macroautophagy. When the capacity of these processes is 
exceeded, α1-antitrypsin polymers accumulates which, depending on the level of 
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accumation, results in oxidative stress and cell death, or proliferation. The final outcome 
is liver failure. Potential interventions are depicted in red boxes. 
 
 
Figure 6. Fates of α1-antitrypsin within the endoplasmic reticulum.  
The nascent α1-antitrypsin protein is translated and enters the endoplasmic reticulum 
(ER) where it undergoes N-linked glycosylation.   Glucose residues are trimmed from α1-
antitrypsin by the action of glucosidases I (GS1) and glucosidases II (GS2), which 
promotes interaction of the nascent protein with the lectin chaperones calnexin (CNX) 
and calreticulin (CRT). This allows the folding of the protein by protein disulphide-
isomerase A3 (ERp57), following which, it is deglycosylated by GS2 248. If folding of the 
α1-antitrypsin protein is correct, it is exported from the ER and trafficked to the Golgi 
apparatus. Conversely, misfolded α1-antitrypsin protein (for example, NHK or Z 
isoforms) is reglycosylated by UDP-glucose:glycoprotein glucosyltransferase 1 
(UGGT1), which allows the reinteraction of misfolded α1-antitrypsin with CNX and CRT 
and refolding by ERp57. This cycle can persist, but misfolded α1-antitrypsin eventually 
undergoes demannosylation by ER α-mannosidase I (ERManI and EDEM). Further 
demannosylation leads to the interaction of α1-antitrypsin with protein OS-9 (OS-9) and 
endoplasmin (GRP94) and delivery to the E3 ubiquitin-protein ligase synoviolin (HRD1) 
complex (containing E3 ubiquitin-protein ligase AMFR (gp78)) for ER associated 
degradation (ERAD)116. Misfolded α1-antitrypsin (for example the NHK isoform) can 
also accumulate in the ER and is speculated to sequester BiP away from the ER stress 
sensors eukaryotic translation initiation factor 2-α kinase 3 (PERK), cyclic-AMP-
dependent transcription factor ATF-6α (ATF6) and serine/threonine-protein 
kinase/endoribonuclease IRE1 (IRE1), leading to activation of the unfolded protein 
response (UPR) and ER stress. By contrast, accumulation of Z α1-antitrypsin results in 
the formation of ordered polymers that lead to the activation of the ER overload response 
(EOR) and upregulation of proinflammatory cytokines. The underlying mechanisms of 
polymer-mediated activation of EOR are poorly understood, but appear to require 
calcium release of calcium from the ER lumen, NF-κB signalling and a proinflammatory 
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response.  Under some circumstances, polymers of α1-antitrypsin can be degraded by 
macroautophagy. 
 
Figure 7. One diagnostic algorithm for A1ATD. A1ATD diagnosis involves 
quantification of α1-antitrypsin levels, genotyping of SERPINA1 and PI typing.  
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Table 1. α1-antitrypsin augmentation therapy observational studies and clinical trials  
 
Clinical trial 
design 
Lead author 
or group 
name 
Year Main outcome  Duration of 
follow up  
Ref
. 
Multicenter, 
randomised 
Chapman 
(RAPID 
Study) 
2015 Slower rate of lung 
tissue loss assessed 
using CT  
2-4 years  
 
142 
Multicentre, 
randomised, 
placebo-
controlled, 
double-blind  
Dirksen 
EXACTLE 
Study) 
 
Dirksen 
2009 
 
 
 
1999 
Trend towards 
slower rate of lung 
tissue loss assessed 
using CT 
 
Trend towards 
slower rate of lung 
tissue loss assessed 
using CT and 
increased mortality  
2-2.5 years  
  
3 years 
 
141 
 
 
 
145 
Observational Seersholm 1997 Reduction in FEV1 
decline in cohort 
with FEV1 31-65% 
>1 year  
 
187 
Observational NHLBI 
Registry 
1998 Slower rate of FEV1 
decline in cohort 
with a baseline FEV1 
between 35-49% 
7.2 years 
 
108 
Observational Lieberman 2000 Reductions in the 
incidence of lung 
infections  
1-10 years 
 
188 
Observational Wencker 2001 Slower rate of FEV1 
decline 
>12 months  
 
189 
Observational Tonelli 2009 Slower rate of FEV1 
decline 
3.5 years 
 
190 
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Table 2. Factors affecting symptoms and QOL in α1-antitrypsin deficient patients with 
COPD139  
Symptom Comment 
Depression Decreased in those in a stable relationship rather than single 
Anxiety Increased in those who are younger and less educated  
Dyspnoea Worse if the patient is single compared with patients who were married 
or in a long-term relationship, and compared with non-α1-antitrypsin 
deficient patients with COPD 
Impaired QOL Poorer compared to non-α1-antitrypsin deficient patients with COPD, 
but less severe above 59 years of age 
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